Bio‑Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved the Marketing Authorization Application for its Secukinumab Injection (BAT2306), indicated for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis – making it the world’s first secukinumab biosimilar and opening a lower‑cost access channel to one of immunology’s biggest blockbuster franchises.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Marketing Authorization Application (MAA) approved |
| Product | Secukinumab Injection (BAT2306) |
| Biosimilar To | Secukinumab (originator brand: Cosentyx, Novartis) |
| Indications | Psoriasis; ankylosing spondylitis (AS); psoriatic arthritis (PsA) |
| Distinction | World’s first secukinumab biosimilar |
| Approval Date | 22 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: BAT2306 – an anti‑human interleukin‑17A (IL‑17A) monoclonal antibody (IgG1κ) and biosimilar to secukinumab (Cosentyx).
- Target: IL‑17A – selectively binds the cytokine, inhibiting its interaction with the IL‑17 receptor and thereby suppressing the release of pro‑inflammatory cytokines and chemokines.
- Disease Biology: IL‑17A is a cytokine generated during the human inflammatory and immune response and plays a crucial role in the pathogenesis of various autoimmune diseases. Increased numbers of IL‑17A‑secreting lymphocytes and elevated IL‑17A levels have been detected in the blood of patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis – validating IL‑17A blockade across all three approved indications.
- Triple‑Indication Scope: Securing the full originator label – skin (psoriasis), joint (PsA) and spine (AS) – in a single biosimilar approval maximizes commercial reach across dermatology, rheumatology and orthopedic channels.
Biosimilar Landscape & Competitive Position
- First‑Mover Advantage: As the world’s first secukinumab biosimilar, BAT2306 captures the initial‑entry position ahead of the global biosimilar field, with potential priority in Chinese tendering and procurement.
- Originator Franchise: Cosentyx is a multi‑billion‑dollar global immunology franchise; biosimilar entry typically drives substantial price erosion and volume expansion, particularly in price‑sensitive markets.
- China Access Impact: With IL‑17A biologics previously constrained by cost in China’s self‑pay and reimbursement mix, a domestic biosimilar could significantly expand treated patient volumes across psoriasis and spondyloarthropathies.
- Bio‑Thera Portfolio: The approval adds a marquee immunology asset to Bio‑Thera’s growing commercial portfolio of biosimilars and innovative antibodies, strengthening its position among China’s leading biopharma platform companies.
Market Impact & Outlook
- Volume‑Based Procurement Path: First‑biosimilar status positions BAT2306 favorably for inclusion in future national or provincial volume‑based procurement (VBP) rounds for biologics, potentially accelerating hospital access.
- Global Expansion Optionality: Worldwide‑first status provides a data and registration foundation for ex‑China filings in other markets as originator patents expire.
- Pricing Dynamics: The launch is expected to pressure originator pricing in China while broadening overall IL‑17A class penetration.
- Next Milestones: Commercial launch and tender access in China; potential international registrations. Timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization, procurement access, pricing, market share capture, and international expansion of BAT2306. Actual results may differ materially due to risks including volume‑based procurement outcomes, competitive biosimilar entry, interchangeability and substitution policies, immunogenicity experience in broader use, and originator pricing responses.-Fineline Info & Tech
